# Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation

> **NCT02666157** · PHASE4 · UNKNOWN · sponsor: **National Cheng-Kung University Hospital** · enrollment: 3672 (estimated)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Dabigatran etexilate
- **DRUG:** Rivaroxaban
- **DRUG:** Apixaban

## Key facts

- **NCT ID:** NCT02666157
- **Lead sponsor:** National Cheng-Kung University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 3672 (ESTIMATED)
- **Last updated:** 2016-02-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02666157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02666157, "Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02666157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*